• Strongest US revenue in years, delivered on a leaner cost base
• Australia's best quarter of revenue since 2022
• Neuro Elite Athletics investment completed with outstanding results

Control Bionics Limited (ASX: CBL) has announced its Activity Report and Appendix 4C for the quarter ended 31 March 2025. The company made solid progress on diversifying future revenue streams and containing costs, with cash of $1.7 million at the end of the quarter. Revenue for the US business over the six months to 31 March 2025 was the highest since FY23, delivered on a leaner cost base following A$700k in annualized savings. Australia also had its best quarter of revenue since 2022, driven by improved NDIS approval times and a strong sales pipeline. The company completed its investment in Neuro Elite Athletics, with the launch customer, Utah Prep Academy, delivering outstanding results for its first batch of athletes. Control Bionics also launched its NeuroStrip software, providing access to a new SaaS revenue stream along with hardware sales. Cash receipts for the quarter exceeded $1.6 million, up from $1.4 million in Q2FY25. The company is focused on six key strategic priorities in FY25, including achieving profitability in core markets, scaling the NeuroNode business, commercializing DROVE, expanding NeuroStrip, accelerating growth, and building a high-performance organization.

Control Bionics is focused on six key strategic priorities in FY25: achieving profitability in core markets, scaling the NeuroNode business, commercializing DROVE, expanding NeuroStrip, accelerating growth, and building a high-performance organization.